Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). This long-term analysis poo...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Mesa, Ruben, Gupta, Vikas, Lavie, David, Dubruille, Viviane, Cambier, Nathalie, Platzbecker, Uwe, Hus, Marek, Xicoy, Blanca, Oh, Stephen T., Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Gerds, Aaron, Egyed, Miklos, Mayer, Jiří, Sacha, Tomasz, Kawashima, Jun, Morris, Marc, Huang, Mei, Harrison, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368854/
https://www.ncbi.nlm.nih.gov/pubmed/37042865
http://dx.doi.org/10.1182/bloodadvances.2022009311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368854/
https://www.ncbi.nlm.nih.gov/pubmed/37042865
http://dx.doi.org/10.1182/bloodadvances.2022009311

Ejemplares similares